arrow
C

Craig A. Portell

university of virginia comprehensive cancer center
H指数:27
被引数:3,008

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Combating CD24 to overcome CD19 CAR-T resistance via induction of innate and adaptive immunity in B-cell malignancies

通过诱导先天性和适应性免疫来对抗CD24,以克服B细胞恶性肿瘤中CD19 CAR-T的耐药性

Leukemia
IF13.4
2026-10-120
OAAI
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

套细胞淋巴瘤在序贯一线 bendamustine-rituximab 和二线 Bruton 酪氨酸激酶抑制剂治疗后的预后

2026-04-250
OAAI
Brentuximab vedotin and dose attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty

Brentuximab vedotin 及剂量调整的化疗免疫疗法在75岁及以上弥漫大B细胞淋巴瘤患者中的应用,并按虚弱程度分析其结局

2026-03-050
PRE
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403

II期研究:将venetoclax加入bendamustine和obinutuzumab用于高风险滤泡性淋巴瘤患者的一线治疗:PrE0403

2025-05-120
OA
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
2024-06-205
OAAI
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
2023-11-179
OAAI
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study
2023-10-193
OAAI
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
2023-06-287
OAAI
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study
2023-01-019
OA